Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Bone

Towards a better management of glucocorticoid-induced osteoporosis?

Nature Reviews Rheumatology volume 13, pages 635–636 (2017)Cite this article

Subjects

A new publication by the ACR provides clear recommendations for the prevention and treatment of osteoporosis in patients being treated with glucocorticoids, but will they improve the historically inadequate management of this patient population?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rizzoli, R., Biver, E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat. Rev. Rheumatol. 11, 98–109 (2015).

    Article  CAS  Google Scholar 

  2. Buckley, L. et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.23279 (2017).

  3. Kanis, J. A. et al. Interpretation and use of FRAX in clinical practice. Osteoporos. Int. 22, 2395–2411 (2011).

    Article  CAS  Google Scholar 

  4. Majumdar, S. R. et al. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids. J. Clin. Endocrinol. Metab. 97, 1236–1242 (2012).

    Article  CAS  Google Scholar 

  5. Kanis, J. A., Johansson, H., Oden, A., McCloskey, E. V. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos. Int. 22, 809–816 (2011).

    Article  CAS  Google Scholar 

  6. Rizzoli, R. et al. Management of glucocorticoid-induced osteoporosis. Calcif. Tissue Int. 91, 225–243 (2012).

    Article  CAS  Google Scholar 

  7. Grossman, J. M. et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 62, 1515–1526 (2010).

    Article  Google Scholar 

  8. Saag, K. G. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346–3355 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva 14, 1211, Switzerland

    René Rizzoli

Authors
  1. René Rizzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to René Rizzoli.

Ethics declarations

Competing interests

The author declares that he has acted as consultant or speaker for EffRx, Labatec, ObsEva and Radius Health.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rizzoli, R. Towards a better management of glucocorticoid-induced osteoporosis?. Nat Rev Rheumatol 13, 635–636 (2017). https://doi.org/10.1038/nrrheum.2017.141

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2017.141

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing